Christine Markert-Hahn

Title: Christine Markert-Hahn: Innovator in Nucleic Acid Methylation Analysis

Introduction

Christine Markert-Hahn is a distinguished inventor based in Penzberg, Germany. With a portfolio of 10 patents, she has made significant contributions to the field of molecular biology, particularly in the area of nucleic acid analysis.

Latest Patents

Her latest patent pertains to a method for bisulfite treatment aimed at determining methylation positions in nucleic acids. This innovative approach involves binding the nucleic acid to a solid phase during the deamination and/or desulfonation steps of the bisulfite reaction. The method allows for the identification of both methylated and non-methylated cytosines. The solid phase used in this process is preferably composed of materials such as glass or silica, with specific examples including glass fleece, glass membranes, or magnetic glass particles. Additionally, her patent includes a kit that contains a bisulfite reagent and a solid phase, enhancing the accessibility of this method for research purposes.

Career Highlights

Christine’s career has included notable positions at companies such as Roche Molecular Systems, Inc. and Epigenomics AG. Her work has focused on advancing the understanding of genomic methylation and its implications in various biological contexts, which has practical applications in research and clinical diagnostics.

Collaborations

Throughout her career, Christine has collaborated with esteemed colleagues including Dirk Block and Frank Bergmann. These partnerships have fostered a dynamic exchange of ideas and insights, contributing to the successful development of her innovative methods.

Conclusion

In summary, Christine Markert-Hahn stands out as a key figure in the realm of nucleic acid research, with her patents reflecting a blend of creativity and scientific acumen. Her work not only furthers our understanding of genetic methylation but also provides essential tools for researchers in the field.